A Phase 1b, Open Label, Multicenter, Dose Escalation Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 08 Jun 2017
At a glance
- Drugs Azintuxizumab-vedotin (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Venetoclax (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors AbbVie
- 01 Jun 2017 Planned End Date changed from 1 Jan 2021 to 28 Apr 2021.
- 01 Jun 2017 Planned primary completion date changed from 1 Jul 2020 to 28 Jul 2020.
- 01 Jun 2017 Status changed from recruiting to withdrawn prior to enrolment as No participants enrolled.